September 6 this year during the International Defense Industry Exhibition in Kielce, PGZ S.A. and Javelin Joint Venture, created as a result of Raytheon's cooperation with Lockheed Martin, signed an agreement to explore the possibility of establishing a final assembly and component production plant in Poland. Additionally, immediately after signing the agreement, representatives of Javelin Joint Venture presented to the president of the management board of PGZ S.A. Sebastian Chwałek, request for quotation for the production of the first components for Javelin missiles at MESKO S.A.


The second day of the MSPO exhibition also brought other agreements with foreign contractors. Under a letter of intent between PGZ and MBDA UK Limited, the parties have committed to jointly develop a new low-cost medium-range missile based on the CAMM family, intended for the armed forces of the UK and Poland. The new concept of the CAMM-MR missile takes into account the needs of the Ministry of Defense and is intended to complement the CAMM and CAMM-ER missiles in the integrated air defense systems of Miecznik, Vistula, Narew and Pilica+ projects.


- The aim of this letter of intent is to map out the future steps that both PGZ and MBDA should take to engage in the design, development and production of CAMM-MR. We are also calling this initiative the Future Common Missile to indicate that it is intended to serve the Polish and British armed forces as a joint product of both parties. A new chapter is opening for PGZ, so as a trusted partner of MBDA, we are highly motivated to engage in cooperation in the area of design and development, including the use of resources such as the Hardware-In-The-Loop Laboratory – said Sebastian Chwałek, President of the Management Board of PGZ S.A.


- The joint works on the new missile are a historic step for our companies and countries. MBDA was established to support the cross-border development of missile systems in Europe, so we are very proud to be working with PGZ and Poland on the new project – said Chris Allam, Managing Director of MBDA UK.